Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-BAFF CAR-T for R/R B-cell ALL and NHL
NCT06346912Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19-BAFF CAR-T in B cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma, sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 years and Treatment-emergent adverse events at 2 years. Started May 2024; status: recruiting.
02
Drugs
CD19-BAFF CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06346912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06346912.